Literature DB >> 15554892

Application of gonadotropin releasing hormone in hypogonadotropic hypogonadism--diagnostic and therapeutic aspects.

Henriette A Delemarre-van de Waal1.   

Abstract

BACKGROUND: Puberty is the result of reactivation of the gonadotropin releasing hormone (GnRH) pulse generator resulting in an increasing release of GnRH by the hypothalamus, which stimulates the gonadotropic cells of the pituitary to synthesize and secrete LH and FSH. Hypogonadotropic hypogonadism (HH) is often the result of GnRH deficiency. The clinical picture is characterized by the absence of pubertal development and infertility. It is difficult to differentiate HH from delayed puberty since low gonadotropin and low testosterone levels are found in both conditions. We hypothesized that long-term GnRH administration may differentiate between the two conditions by a difference in the increase of gonadotropins, the idea being that in normal delayed puberty the pituitary of the patient has been primed with GnRH during the fetal and early postnatal period. PATIENTS: Seventeen adolescents suspected of having hypogonadotropic hypogonadism were treated with pulsatile GnRH for 7 days. At the present time, the diagnosis of these patients is known and the results of the long-term GnRH stimulation have been evaluated according to the present diagnosis.
RESULTS: The results show that the increase in gonadotropins following GnRH treatment is similar in both conditions. Therefore, at a prepubertal age a normal delayed puberty cannot be distinguished from hypogonadotropic hypogonadism using long-term GnRH stimulation. Long-term pulsatile GnRH treatment is a physiological therapy for the induction of puberty. Unlike testosterone it has the advantage of stimulation of testicular growth and fertility, as well as virilization, in males. We have treated 68 male patients with HH with pulsatile GnRH. The results show testicular growth and virilization in all the patients and spermatogenesis in 58 patients. Wearing a portable pump is cumbersome. However, the patients were very motivated and adapted very easily to this inconvenience. When spermatogenesis had developed, GnRH treatment was changed to human chorionic gonadotropin (hCG) administration 1-2 times per week intramuscularly or subcutaneously. During hCG therapy spermatogenesis was maintained or even improved. At least ten patients fathered children.
CONCLUSION: Pulsatile GnRH cannot distinguish between a normal delayed puberty and a hypothalamic defect in still prepubertal patients. Pulsatile GnRH offers an appropriate way to initiate testicular growth including virilization and fertility in males with hypogonadotropic hypogonadism.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15554892     DOI: 10.1530/eje.0.151u089

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  14 in total

1.  Male reproductive health after childhood, adolescent, and young adult cancers: a report from the Children's Oncology Group.

Authors:  Lisa B Kenney; Laurie E Cohen; Margarett Shnorhavorian; Monika L Metzger; Barbara Lockart; Nobuko Hijiya; Eileen Duffey-Lind; Louis Constine; Daniel Green; Lillian Meacham
Journal:  J Clin Oncol       Date:  2012-05-29       Impact factor: 44.544

Review 2.  Neonatal gonadotropin therapy in male congenital hypogonadotropic hypogonadism.

Authors:  Claire Bouvattier; Luigi Maione; Jérôme Bouligand; Catherine Dodé; Anne Guiochon-Mantel; Jacques Young
Journal:  Nat Rev Endocrinol       Date:  2011-10-18       Impact factor: 43.330

3.  Application of hormonal treatment in hypogonadotropic hypogonadism: more than ten years experience.

Authors:  Luo Yang; Si Xiao Zhang; Qiang Dong; Zi Bing Xiong; Xiang Li
Journal:  Int Urol Nephrol       Date:  2011-10-12       Impact factor: 2.370

4.  Medical treatment in gender dysphoric adolescents endorsed by SIAMS-SIE-SIEDP-ONIG.

Authors:  A D Fisher; J Ristori; E Bandini; S Giordano; M Mosconi; E A Jannini; N A Greggio; A Godano; C Manieri; C Meriggiola; V Ricca; D Dettore; M Maggi
Journal:  J Endocrinol Invest       Date:  2014-05-27       Impact factor: 4.256

5.  Outcome of gonadotropin therapy for male infertility due to hypogonadotrophic hypogonadism.

Authors:  Rafif Farhat; Fatma Al-zidjali; Ali S Alzahrani
Journal:  Pituitary       Date:  2010-06       Impact factor: 4.107

Review 6.  Male hypogonadism.

Authors:  Andrea M Isidori; Elisa Giannetta; Andrea Lenzi
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

Review 7.  Gonadotropins in doping: pharmacological basis and detection of illicit use.

Authors:  U-H Stenman; K Hotakainen; H Alfthan
Journal:  Br J Pharmacol       Date:  2008-04-14       Impact factor: 8.739

8.  Genetics of isolated hypogonadotropic hypogonadism: role of GnRH receptor and other genes.

Authors:  Karges Beate; Neulen Joseph; de Roux Nicolas; Karges Wolfram
Journal:  Int J Endocrinol       Date:  2011-12-21       Impact factor: 3.257

9.  Treatment situation of male hypogonadotropic hypogonadism in pediatrics and proposal of testosterone and gonadotropins replacement therapy protocols.

Authors:  Naoko Sato; Tomonobu Hasegawa; Yukihiro Hasegawa; Osamu Arisaka; Keiichi Ozono; Shin Amemiya; Toru Kikuchi; Hiroyuki Tanaka; Shohei Harada; Ichiro Miyata; Toshiaki Tanaka
Journal:  Clin Pediatr Endocrinol       Date:  2015-05-15

10.  A network investigation on idiopathic hypogonadotropic hypogonadism in china.

Authors:  Weiwei Zhao; Hongying Ye; Xiaolong Zhao; Zhaoyun Zhang; Shouyue Sun; Yiran Jiang; Min He; Cheng Xu; Renming Hu; Yiming Li
Journal:  Int J Endocrinol       Date:  2013-12-09       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.